On blockbuster path, Argenx's red-hot Vyvgart comes up short in thrombocytopenia trial

On a roll with Vyvgart—which is on its way to blockbuster sales in just its second year on the market for generalized myasthenia gravis (gMG)—argenx’s heat check in another indication has missed badly.